Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYNAVOY vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8; undergoes glucuronidation by UGT1A9.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 94–96% bound to plasma proteins, primarily albumin.
82–88% bound to plasma proteins (primarily albumin).
Apparent volume of distribution is about 50 L (approximately 0.7 L/kg), indicating extensive tissue distribution.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Absolute oral bioavailability is approximately 70% under fasting conditions. Food does not significantly affect absorption.
Oral: 65–80% (median 73%)
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min) not on hemodialysis, reduce dose to 75 mg orally twice daily (adults) or 75 mg/m2 per dose (pediatric, max 75 mg per dose). End-stage renal disease on hemodialysis: no data, consider risks vs benefits.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: no adjustment. Child-Pugh B: reduce to 75 mg orally twice daily (adults) or 75 mg/m2 per dose (pediatric, max 75 mg per dose). Child-Pugh C: reduce to 50 mg orally twice daily (adults) or 50 mg/m2 per dose (pediatric, max 50 mg per dose).
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
For patients aged ≥28 days and <18 years with body surface area (BSA) ≥1.0 m2: 100 mg orally twice daily. For BSA <1.0 m2: 100 mg/m2 per dose (maximum 100 mg per dose) orally twice daily. Administer with or without food.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment recommended. Clinical studies included patients ≥65 years; no overall differences in safety or efficacy observed. Monitor for adverse effects due to potential age-related comorbidities and renal/hepatic function decline.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
None.
None
Cardiomyopathy: Assess left ventricular ejection fraction (LVEF) before initiation, monitor during treatment, and withhold or permanently discontinue based on severity.,Ocular toxicity: Monitor for retinal vein occlusion, retinal pigment epithelial detachment, and visual disturbances; conduct ophthalmic evaluations.,Dermatologic toxicity: Manage rash, acneiform dermatitis, and hand-foot skin reactions with supportive care; dose interruption or reduction may be required.,Gastrointestinal toxicity: Diarrhea, nausea, vomiting, and stomatitis are common; manage with antiemetics and antidiarrheals.,Venous thromboembolism (VTE): Monitor for signs and symptoms; discontinue if life-threatening VTE occurs.,Rhabdomyolysis: Monitor creatine kinase (CK) levels; withhold if CK elevation with muscle symptoms occurs.,Embryo-fetal toxicity: Can cause fetal harm; advise females of reproductive potential and males with female partners of childbearing potential to use effective contraception.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
None.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
No specific food interactions. Maintain adequate hydration. Avoid grapefruit juice if taking concomitant CYP3A4 substrates. No dietary restrictions required.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
LYNAVOY (ribociclib) is contraindicated in pregnancy. Based on its mechanism of action (CDK4/6 inhibition) and animal studies, it can cause fetal harm. First trimester: High risk of embryotoxicity and teratogenicity; avoid pregnancy. Second and third trimesters: Continued risk; not recommended. Women of childbearing potential must use effective contraception during therapy and for at least 3 weeks after last dose.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
It is unknown if LYNAVOY is excreted in human milk; however, ribociclib and its metabolites are present in rat milk. Due to potential serious adverse effects in nursing infants, breastfeeding is not recommended during treatment and for at least 3 weeks after the last dose. M/P ratio not available.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
LYNAVOY is contraindicated in pregnancy and no dose adjustment recommendations exist. If a patient becomes pregnant during treatment, discontinue LYNAVOY immediately. No pharmacokinetic data are available to guide dose changes during pregnancy.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
LYNAVOY (lutetium Lu 177 vipivotide tetraxetan) is a PSMA-targeted radioligand therapy for PSMA-positive metastatic castration-resistant prostate cancer. Requires premedication with antiemetics. Monitor for myelosuppression, xerostomia, and renal toxicity. Ensure adequate hydration prior to infusion. Contraindicated in severe bone marrow suppression.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
You are receiving a radioactive drug that targets prostate cancer cells. You may experience dry mouth, nausea, or low blood counts.,Drink plenty of fluids before and after treatment to protect your kidneys.,Avoid close contact with pregnant women, infants, and children for a period of time as instructed by your healthcare team.,Use effective contraception during treatment and for several months after the last dose.,Report any signs of infection, bleeding, or unusual fatigue to your doctor immediately.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYNAVOY vs AGRYLIN, answered by our medical review team.
LYNAVOY is a Antineoplastic Agent that works by LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYNAVOY and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYNAVOY is: LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYNAVOY and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYNAVOY is classified as Category C. LYNAVOY (ribociclib) is contraindicated in pregnancy. Based on its mechanism of action (CDK4/6 inhibition) and animal studies, it can cause fetal harm. First trimester: High risk o. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.